At a Glance
- Company: Autolus Therapeutics
- Actions: 13% headcount cut, manufacturing double
- Savings: $15M annual from 2027
- Revenue guide: $120M-$135M AUCATZYL 2026
- Cash runway: Q4 2027
What happened?
Autolus Therapeutics announced a strategic initiative on 29 April 2026 to improve efficiency and reduce costs, including a 13% workforce reduction across all areas. The plan incurs $8M restructuring charges (mostly H1 2026) while reiterating 2026 AUCATZYL net revenue of $120M-$135M.
Why does it matter?
Post-2025 AUCATZYL launch (ALL CAR-T), Autolus focuses on gross margin positivity and profitability path. Cuts enable scalable growth amid clinical expansion (CATULUS, LUMINA, BOBCAT), balancing cost discipline with manufacturing ramp.
Who’s behind it?
CEO Dr Christian Itin leads; impacts all functions. Pipeline on track: CATULUS (pivotal paed r/r ALL), LUMINA (lupus nephritis), BOBCAT (progressive MS).
How was it achieved?
Optimise manufacturing model, enhance automation, develop next-gen platform. Doubles 2026 commercial/clinical output despite cuts.
What’s next?
Positive gross margin 2026; detailed manufacturing update mid-2026. Cash to Q4 2027 supports launches/pivotal trials.
What are people saying?
CEO Christian Itin: “Optimising operating model… enhance margins, support scalable growth.”